المؤلفون: Wollner, Gregor, Zimpfer, Daniel, Manduric, Marina, Laufer, Günther, Rieger, Armin, Sandner, Sigrid E.

المصدر: Journal of Cardiac Surgery; Oct2020, Vol. 35 Issue 10, p2543-2549, 7p, 5 Charts, 3 Graphs

مصطلحات موضوعية: HIV infections, CORONARY artery bypass, HIGHLY active antiretroviral therapy, HIV infection complications, STROKE, SURGICAL complications, CARDIOVASCULAR diseases, RETROSPECTIVE studies, MYOCARDIAL infarction, TREATMENT effectiveness, CORONARY artery disease, DISEASE complications

الشركة/الكيان: MEDIZINISCHE Universitat Wien

مستخلص: Background: With early and effective antiretroviral therapy and improved survival for persons living with human immunodeficiency virus infection (PLHIV), this patient population now faces an increasingly elevated risk of cardiovascular disease. However, the data on outcomes after coronary artery bypass grafting (CABG) for revascularization of coronary artery disease (CAD) in HIV+ patients is limited.Methods: We conducted a retrospective analysis of 16 patients undergoing isolated CABG at the Medical University of Vienna from 2005 to 2018, who were HIV+ on admission. The primary endpoint of the study was survival. Secondary endpoints included the components of major adverse cardiac and cerebrovascular events (MACCE): cardiovascular death, stroke, myocardial infarction (MI), and repeat revascularization.Results: Patients were followed for a median of 49 months (range, 7-142 months). Survival was 100% and 90% at 1 and 3 years after CABG, respectively. There were no strokes. MI and subsequent repeat revascularization were observed in two patients.Conclusion: CABG provides excellent short- and midterm survival and freedom from MACCE in HIV+ patients with CAD requiring revascularization. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Cardiac Surgery is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Sandner, Sigrid¹ (AUTHOR), Gaudino, Mario² (AUTHOR) mfg9004@med.cornell.edu

المصدر: Journal of Cardiac Surgery. Aug2021, Vol. 36 Issue 8, p2802-2804. 3p.

مصطلحات موضوعية: *ACUTE coronary syndrome, *TICAGRELOR, *CORONARY artery bypass, *MYOCARDIAL infarction, *ATHEROSCLEROSIS, *REOPERATION, *CORONARY artery disease

مستخلص: Given the lack of established benefit, routine P2Y12 receptor inhibitor pretreatment in NSTE-ACS is not recommended in patients in whom the coronary anatomy is not known and early invasive management is planned, although it may be considered for patients with delayed invasive management.3 However, P2Y12 receptor inhibitor pretreatment may increase bleeding risk and delay surgery after diagnostic angiography in patients for whom CABG is indicated. In addition, in studies investigating the association of P2Y12 receptor inhibitors and perioperative bleeding risk a surgical bleeding site was identified in up to 55% of patients undergoing reoperation for bleeding,5,14 potentially confounding reports of increased bleeding with ticagrelor. Hansson et al.10 studied the incidence of CABG-related bleeding using the Bleeding Academic Research Consortium (BARC) classification11 in relation to P2Y12 receptor inhibitor discontinuation periods in a retrospective analysis of 2244 ACS patients referred for CABG on DAPT with either ticagrelor or clopidogrel. [Extracted from the article]

المؤلفون: Sandner, Sigrid¹ (AUTHOR) sigrid.sandner@meduniwien.ac.at, Redfors, Björn² (AUTHOR)

المصدر: Journal of Cardiac Surgery. Jul2022, Vol. 37 Issue 7, p1978-1979. 2p.

مستخلص: Notably, only 4 new SVG occlusions and 2 new SVG stenoses occurred between years 1 and 2, with no significant differences between the treatment arms ( I p i = .41). The rate of SVG occlusion in the 142 patients who consented to the extended study and underwent imaging at 2 years after CABG did not differ significantly between the treatment groups (ticagrelor 13.2%, aspirin 15.7%, I p i = .71). Keywords: coronary artery bypass; patency; saphenous vein graft; ticagrelor EN coronary artery bypass patency saphenous vein graft ticagrelor 1978 1979 2 06/06/22 20220701 NES 220701 The Ticagrelor Antiplatelet therapy to Reduce Graft Events and Thrombosis (TARGET) trial randomized 250 patients after coronary artery bypass grafting (CABG) to ticagrelor monotherapy or aspirin monotherapy. [Extracted from the article]